Westlake Village-based MannKind Corporation saw shares climb 8% on Jan. 2 after the company announced entering into a royalty purchase agreement of up to $200 million. MannKind, a biotechnology company that develops treatments for diabetes and pulmonary arterial hypertension, sold a 1% royalty in net sales of Tyvaso DPI to Sagard Healthcare on Dec. 27.
By Ben Glickman Shares of MannKind rose Tuesday after the drugmaker sold part of its royalty interest in Tyvaso DPI for $200 million. The stock was up 6.6%.
Phathom Pharmaceuticals Announces Expansion Of Existing Loan And Security Agreement With Hercules Capital menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Servier drug Tibsovo is now approved for treating advanced cases of myelodysplastic syndrome that have an IDH1 mutation. It’s the first approval of a targeted therapy for this type of cancer.
Netherlands-based uniQure N.V
said on Monday it would sell a portion of the royalty
rights for its blood disorder gene therapy Hemgenix to
HealthCare Royalty and Sagard Healthcare for up to $400. | May 15, 2023